ME LD107

Requires MaineCare and private health insurers (individual, group, and HMO policies) to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases when supported by FDA approval, CMS coverage determinations, or nationally recognized clinical practice guidelines

Defines biomarker testing broadly to include single analyte tests, multiplex panel tests, protein expression analysis, and whole exome, genome, and transcriptome sequencing

Mandates prior authorization decisions within 72 hours for non-urgent requests and 24 hours for urgent requests when utilization review is required

Requires coverage to be delivered in a manner that limits disruptions in care, including avoiding the need for multiple biopsies or biological specimen samples

Applies to insurance policies that take effect or are renewed on or after January 1, 2026